| Titolo |
Pubblicato in |
Anno |
| Current and Emerging Biomarkers Predicting Bone Metastasis Development |
FRONTIERS IN ONCOLOGY |
2020 |
| Dynamic changes of receptor activator of nuclear factor-κB expression in circulating tumor cells during denosumab predict treatment effectiveness in metastatic breast cancer |
SCIENTIFIC REPORTS |
2020 |
| Erratum: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples (vol 39, 95, 2020) |
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
2020 |
| Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary |
JCO ONCOLOGY PRACTICE |
2020 |
| Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma |
TUMORI |
2020 |
| Regression of papillary thyroid cancer during nivolumab for renal cell cancer |
EUROPEAN THYROID JOURNAL |
2020 |
| COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management |
EXPERT OPINION ON BIOLOGICAL THERAPY |
2020 |
| Efficacy of third-line anti-EGFR-based treatment (tx) versus (vs) Regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) |
JOURNAL OF CLINICAL ONCOLOGY |
2020 |
| Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment |
ESMO OPEN |
2020 |
| Identification of aneuploid circulating tumor cells in soft-tissue sarcoma patients: a pilot study |
ONCOLOGY |
2020 |
| Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: a review |
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
2020 |
| Is There Still a Role for Endocrine Therapy Alone in HR+/HER2-Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies |
BREAST CARE |
2020 |
| Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis |
ESMO OPEN |
2020 |
| The emerging role of PARP inhibitors in prostate cancer |
EXPERT REVIEW OF ANTICANCER THERAPY |
2020 |
| Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab |
GASTRIC CANCER |
2020 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial |
THE LANCET ONCOLOGY |
2020 |
| Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study |
JCO PRECISION ONCOLOGY |
2020 |
| Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report |
THE BREAST JOURNAL |
2020 |
| Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis (Targeted Oncology, (2020), 15, 4, (495-501), 10.1007/s11523-020-00732-y) |
TARGETED ONCOLOGY |
2020 |
| Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report |
THE BREAST JOURNAL |
2020 |
